No abstract available
Keywords:
drug development; drug resistance; hepatocellular carcinoma; next generation sequencing; recurrence; regorafenib; survival.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / mortality
-
Carcinoma, Hepatocellular / pathology*
-
Drug Discovery
-
Drug Resistance, Neoplasm
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / mortality
-
Liver Neoplasms / pathology*
-
Phenylurea Compounds / administration & dosage
-
Phenylurea Compounds / adverse effects
-
Phenylurea Compounds / therapeutic use*
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Retreatment
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Phenylurea Compounds
-
Pyridines
-
regorafenib